0001354488-16-006370.txt : 20160226 0001354488-16-006370.hdr.sgml : 20160226 20160225203410 ACCESSION NUMBER: 0001354488-16-006370 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160225 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20160226 DATE AS OF CHANGE: 20160225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 161457650 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 blfs_8k.htm CURRENT REPORT blfs_8k.htm
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

______________________________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934


February 25, 2016
Date of report (Date of earliest event reported)

____________________________________


BIOLIFE SOLUTIONS, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware
  
0-18710
  
94-3076866
(State or Other Juris-
  
(Commission File No.)
  
(IRS Employer
diction of Incorporation)
      
Identification No.)

3303 Monte Villa Parkway, Bothell, WA 98021
(Address of principal executive offices, including zip code)

(425) 402-1400
(Registrant’s telephone number, including area code)

____________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 1.01 Entry Into a Material Definitive Agreement.
 
On February 25, 2016, subsequent to BioLife Solutions, Inc. (the “Company”) filing its annual report on Form 10-K, the Company and Daphne Taylor, the Company’s Chief Financial Officer, entered into an amendment to Ms. Taylor’s employment agreement dated February 19, 2015 (the “Amendment”).  The Amendment provides that upon Ms. Taylor’s voluntary resignation she is entitled to receive severance pay of six months’ salary, plus any accrued and unpaid salary, unused vacation time and reimbursable business expenses, subject to appropriate deductions and withholdings.  Such severance payments are subject to the Company and Ms. Taylor signing, within 30 days following Ms. Taylor’s resignation, and Ms. Taylor not rescinding, as may be permitted by law, a general release of claims in a form acceptable to the Company.
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On February 25, 2016, following the signing of the Amendment, Ms. Taylor resigned from all positions with the Company and its subsidiary effectively immediately, and Michael Rice, the Company’s President and Chief Executive Officer, was appointed as the Company’s principal financial and accounting officer.  The information with respect to Mr. Rice that is required by Items 401(b), (d), (e) and 404(e) of Regulation S-K is incorporated by reference from the Company’s annual report on Form 10-K for the year ended December 31, 2015, as filed on February 25, 2016.
 
 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: February 25, 2016
  BIOLIFE SOLUTIONS, INC.  
       
 
By:
/s/ Michael Rice  
    Michael Rice  
   
President and Chief Financial Officer